tetano
Editor, Senior Moderator
Vaccine. 2016 May 21. pii: S0264-410X(16)30311-5. doi: 10.1016/j.vaccine.2016.05.021. [Epub ahead of print]
[h=1]Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies.[/h] H?quet D[SUP]1[/SUP], Pascual M[SUP]2[/SUP], Lartey S[SUP]3[/SUP], Pathirana RD[SUP]3[/SUP], Bredholt G[SUP]3[/SUP], Hoschler K[SUP]4[/SUP], Hullin R[SUP]5[/SUP], Meylan P[SUP]6[/SUP], Cox RJ[SUP]7[/SUP], Manuel O[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We analyzed the impact of the anti-T-cell agents basiliximab and antithymocyte globulins (ATG) on antibody and cell-mediated immune responses after influenza vaccination in solid-organ transplant recipients.
[h=4]METHODS:[/h] 71 kidney and heart transplant recipients (basiliximab [n=43] and ATG [n=28]) received the trivalent influenza vaccine. Antibody responses were measured at baseline and 6 weeks post-vaccination by hemagglutination inhibition assay; T-cell responses were measured by IFN-γ ELISpot assays and intracellular cytokine staining (ICS); and influenza-specific memory B-cell (MBC) responses were evaluated using ELISpot.
[h=4]RESULTS:[/h] Median time of vaccination from transplantation was 29 months (IQR 8-73). Post-vaccination seroconversion rates were 26.8% for H1N1, 34.1% for H3N2 and 4.9% for influenza B in the basiliximab group and 35.7% for H1N1, 42.9% for H3N2 and 14.3% for influenza B in the ATG group (p=0.44, p=0.61, and p=0.21, respectively). The number of influenza-specific IFN-γ-producing cells increased significantly after vaccination (from 35 to 67.5 SFC/10[SUP]6[/SUP] PBMC, p=0.0007), but no differences between treatment groups were observed (p=0.88). Median number of IgG-MBC did not increase after vaccination (H1N1, p=0.94; H3N2 p=0.34; B, p=0.79), irrespective of the type of anti-T-cell therapy.
[h=4]CONCLUSIONS:[/h] After influenza vaccination, a significant increase in antibody and T-cell immune responses but not in MBC responses was observed in transplant recipients. Immune responses were not significantly different between groups that received basiliximab or ATG.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Biological agents; Immunogenicity; Induction; Prevention; Viral infection
PMID: 27219339 [PubMed - as supplied by publisher]
[h=1]Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies.[/h] H?quet D[SUP]1[/SUP], Pascual M[SUP]2[/SUP], Lartey S[SUP]3[/SUP], Pathirana RD[SUP]3[/SUP], Bredholt G[SUP]3[/SUP], Hoschler K[SUP]4[/SUP], Hullin R[SUP]5[/SUP], Meylan P[SUP]6[/SUP], Cox RJ[SUP]7[/SUP], Manuel O[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We analyzed the impact of the anti-T-cell agents basiliximab and antithymocyte globulins (ATG) on antibody and cell-mediated immune responses after influenza vaccination in solid-organ transplant recipients.
[h=4]METHODS:[/h] 71 kidney and heart transplant recipients (basiliximab [n=43] and ATG [n=28]) received the trivalent influenza vaccine. Antibody responses were measured at baseline and 6 weeks post-vaccination by hemagglutination inhibition assay; T-cell responses were measured by IFN-γ ELISpot assays and intracellular cytokine staining (ICS); and influenza-specific memory B-cell (MBC) responses were evaluated using ELISpot.
[h=4]RESULTS:[/h] Median time of vaccination from transplantation was 29 months (IQR 8-73). Post-vaccination seroconversion rates were 26.8% for H1N1, 34.1% for H3N2 and 4.9% for influenza B in the basiliximab group and 35.7% for H1N1, 42.9% for H3N2 and 14.3% for influenza B in the ATG group (p=0.44, p=0.61, and p=0.21, respectively). The number of influenza-specific IFN-γ-producing cells increased significantly after vaccination (from 35 to 67.5 SFC/10[SUP]6[/SUP] PBMC, p=0.0007), but no differences between treatment groups were observed (p=0.88). Median number of IgG-MBC did not increase after vaccination (H1N1, p=0.94; H3N2 p=0.34; B, p=0.79), irrespective of the type of anti-T-cell therapy.
[h=4]CONCLUSIONS:[/h] After influenza vaccination, a significant increase in antibody and T-cell immune responses but not in MBC responses was observed in transplant recipients. Immune responses were not significantly different between groups that received basiliximab or ATG.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Biological agents; Immunogenicity; Induction; Prevention; Viral infection
PMID: 27219339 [PubMed - as supplied by publisher]